Translate
Gilead Sciences Inc
Gilead Sciences Inc
GILD · NASDAQ
$140.45USD
1.42 (1.02%)
Press Releases
Market Cap
$173.41 B
Volume
$29.44 B
EPS
$6.78
Revenue
$29.44 B
P/E Ratio
20.6062
About
Gilead Sciences Inc (NASDAQ:GILD) — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 23 2026
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
Mar 2 2026
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
Feb 25 2026
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
Feb 23 2026
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
Feb 17 2026
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
Financials
Revenue
$29.44 B
Market Cap
$173.41 B
P/E Ratio
20.61
EPS
6.78
Dividend Yield
2.25%